{"organizations": [], "uuid": "032f630c3bd1337ddd093ad98c22ba61323cf9e2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-daiichi-sankyo-aligns-us-commercia/brief-daiichi-sankyo-aligns-u-s-commercial-operations-to-current-portfolio-upcoming-cancer-pipeline-idUSFWN1QI1I2", "country": "US", "domain_rank": 408, "title": "BRIEF-Daiichi Sankyo Aligns U.S. Commercial Operations To Current Portfolio, Upcoming Cancer Pipeline", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T22:02:00.000+02:00", "replies_count": 0, "uuid": "032f630c3bd1337ddd093ad98c22ba61323cf9e2"}, "author": "", "url": "https://www.reuters.com/article/brief-daiichi-sankyo-aligns-us-commercia/brief-daiichi-sankyo-aligns-u-s-commercial-operations-to-current-portfolio-upcoming-cancer-pipeline-idUSFWN1QI1I2", "ord_in_thread": 0, "title": "BRIEF-Daiichi Sankyo Aligns U.S. Commercial Operations To Current Portfolio, Upcoming Cancer Pipeline", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "daiichi sankyo", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "sankyo", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "daiichi", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 28, 2018 / 8:02 PM / Updated 12 minutes ago BRIEF-Daiichi Sankyo Aligns U.S. Commercial Operations To Current Portfolio, Upcoming Cancer Pipeline Reuters Staff Feb 28 (Reuters) - Daiichi Sankyo : * DAIICHI SANKYO, INC. ALIGNS U.S. COMMERCIAL OPERATIONS TO CURRENT PORTFOLIO AND UPCOMING CANCER PIPELINE * DAIICHI SANKYO - ‍AS PART OF REORGANIZATION, CO WILL REDUCE HEADCOUNT BY ABOUT 280 EMPLOYEES FROM VARIOUS LOCATIONS IN THE U.S.​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-28T22:02:00.000+02:00", "crawled": "2018-02-28T22:28:23.032+02:00", "highlightTitle": ""}